Identification of T cell epitopes on hepatitis B surface antigen.

Research output: Contribution to journalReview article

Abstract

The antigenic sites for human T lymphocytes on hepatitis B surface antigen (HBsAg) have been studied using synthetic peptides. The results indicate that aminoacid residues 24-28 of HBsAg (located near the amino terminus of the HBsAg molecule) constitute an immunodominant "helper" determinant, whereas residues 17-18 and/or 34-36 represent a major "suppressor" epitope. However, non responsiveness to currently used hepatitis B virus (HBV) vaccines (employing the whole HBsAg molecule) does not depend, in the vast majority of cases, on suppressor T cells. In vivo experiments with synthetic peptide vaccines are needed to verify the possibility of enhancing the production of protective antibodies against the hepatitis B virus.

Original languageEnglish
Pages (from-to)37-40
Number of pages4
JournalAnnali dell'Istituto Superiore di Sanita
Volume27
Issue number1
Publication statusPublished - 1991
Externally publishedYes

Fingerprint

T-Lymphocyte Epitopes
Hepatitis B Surface Antigens
T-Lymphocytes
Hepatitis B Antibodies
Immunodominant Epitopes
Hepatitis B Vaccines
Synthetic Vaccines
Subunit Vaccines
Hepatitis B virus
Epitopes
Peptides

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Identification of T cell epitopes on hepatitis B surface antigen. / Vento, S.

In: Annali dell'Istituto Superiore di Sanita, Vol. 27, No. 1, 1991, p. 37-40.

Research output: Contribution to journalReview article

@article{74d90221ef0f4799a002ad5793837a64,
title = "Identification of T cell epitopes on hepatitis B surface antigen.",
abstract = "The antigenic sites for human T lymphocytes on hepatitis B surface antigen (HBsAg) have been studied using synthetic peptides. The results indicate that aminoacid residues 24-28 of HBsAg (located near the amino terminus of the HBsAg molecule) constitute an immunodominant {"}helper{"} determinant, whereas residues 17-18 and/or 34-36 represent a major {"}suppressor{"} epitope. However, non responsiveness to currently used hepatitis B virus (HBV) vaccines (employing the whole HBsAg molecule) does not depend, in the vast majority of cases, on suppressor T cells. In vivo experiments with synthetic peptide vaccines are needed to verify the possibility of enhancing the production of protective antibodies against the hepatitis B virus.",
author = "S. Vento",
year = "1991",
language = "English",
volume = "27",
pages = "37--40",
journal = "Annali dell'Istituto Superiore di Sanita",
issn = "0021-2571",
publisher = "Istituto Superiore di Sanita",
number = "1",

}

TY - JOUR

T1 - Identification of T cell epitopes on hepatitis B surface antigen.

AU - Vento, S.

PY - 1991

Y1 - 1991

N2 - The antigenic sites for human T lymphocytes on hepatitis B surface antigen (HBsAg) have been studied using synthetic peptides. The results indicate that aminoacid residues 24-28 of HBsAg (located near the amino terminus of the HBsAg molecule) constitute an immunodominant "helper" determinant, whereas residues 17-18 and/or 34-36 represent a major "suppressor" epitope. However, non responsiveness to currently used hepatitis B virus (HBV) vaccines (employing the whole HBsAg molecule) does not depend, in the vast majority of cases, on suppressor T cells. In vivo experiments with synthetic peptide vaccines are needed to verify the possibility of enhancing the production of protective antibodies against the hepatitis B virus.

AB - The antigenic sites for human T lymphocytes on hepatitis B surface antigen (HBsAg) have been studied using synthetic peptides. The results indicate that aminoacid residues 24-28 of HBsAg (located near the amino terminus of the HBsAg molecule) constitute an immunodominant "helper" determinant, whereas residues 17-18 and/or 34-36 represent a major "suppressor" epitope. However, non responsiveness to currently used hepatitis B virus (HBV) vaccines (employing the whole HBsAg molecule) does not depend, in the vast majority of cases, on suppressor T cells. In vivo experiments with synthetic peptide vaccines are needed to verify the possibility of enhancing the production of protective antibodies against the hepatitis B virus.

UR - http://www.scopus.com/inward/record.url?scp=0026041460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026041460&partnerID=8YFLogxK

M3 - Review article

VL - 27

SP - 37

EP - 40

JO - Annali dell'Istituto Superiore di Sanita

JF - Annali dell'Istituto Superiore di Sanita

SN - 0021-2571

IS - 1

ER -